As Vice President of the RDTC, Cat works with rare disease patient-based foundations, researchers, and academic and industry partners to engineer precision cellular and mouse models to accelerate the discovery and implementation of genetic therapies including gene editing, gene replacement, and antisense oligonucleotides (ASOs). With utmost focus on rigor and translatability of preclinical research, Cat has worked extensively with the rare disease community to advance the creation, implementation, and optimization of robust, scalable platforms for precision therapeutic development and testing. With an extensive network of passionate collaborators across the field, Cat excitedly looks forward to the years ahead sure to be filled with exciting work, meaningful discoveries, and scientific advances to revolutionize the rare disease space.
Cat received a B.S. In Biochemistry from the University of Pittsburgh in Pennsylvania. She completed her Ph.D. at the University of Maine, Orono followed by a postdoctoral fellowship at Duke University Medical Center in Durham before joining the JAX team. Cat also has an M.B.A. from Husson University. A full list of Cat's publications can be reviewed here: My Bibliography - NCBI.